Elysium Health
Financials
Estimates*
USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | 4.6m | 7.1m | 7.1m | 4.7m | 9.7m | 10.1m |
% growth | - | 55 % | - | (34 %) | 107 % | 4 % |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Seed | ||
N/A | $6.2m | Series A | |
N/A | Series A | ||
$20.0m | Series B | ||
$5.0m | Debt | ||
$40.0m | Series C | ||
N/A | N/A | Series C | |
N/A | Series C | ||
Total Funding | AUD102m |
Related Content
Recent News about Elysium Health
EditElysium Health operates in the life sciences sector, focusing on developing scientifically-backed health products aimed at improving cellular aging, DNA health, and brain function. The company serves health-conscious consumers who are interested in proactive health management and longevity. Elysium Health's business model revolves around direct-to-consumer sales of its flagship products, including Basis, Matter, and Index. Basis is a supplement clinically proven to increase NAD levels, which are essential for cellular health. Matter is designed to slow age-related brain atrophy with a specific B vitamin complex. Index is an at-home test that uses epigenetics technology to determine biological age. The company generates revenue through online sales and subscription models, ensuring a steady stream of income. Elysium Health differentiates itself through its commitment to scientific research and partnerships with leading academic institutions.
Keywords: cellular aging, DNA health, brain function, NAD levels, epigenetics, biological age, supplements, direct-to-consumer, scientific research, longevity.